Pharmaceuticals,
Journal Year:
2022,
Volume and Issue:
15(3), P. 335 - 335
Published: March 9, 2022
Numerous
research
reports
have
witnessed
dramatic
advancements
in
cancer
therapeutic
approaches
through
immunotherapy.
Blocking
immunological
checkpoint
pathways
(mechanisms
employed
by
malignant
cells
to
disguise
themselves
as
normal
human
body
components)
has
emerged
a
viable
strategy
for
developing
anticancer
immunity.
Through
the
development
of
effective
immune
inhibitors
(ICIs)
multiple
carcinomas,
advances
immunity
expedited
major
breakthrough
therapy.
variety
ICIs,
such
PD-1
(programmed
cell
death-1),
programmed
death-ligand
1
(PD-L1),
and
cytotoxic
T-lymphocyte-associated
protein
4
(CTLA-4)
improved
system’s
efficacy
combating
cells.
Recent
studies
also
supported
fact
that
ICIs
combined
with
other
potent
antitumor
candidates,
angiogenic
agents,
could
be
solid
promising
chemopreventive
approach
improving
effectiveness
inhibitors.
Immune
blockade
aided
antiangiogenesis
lowering
vascular
endothelial
growth
factor
expression
alleviating
hypoxia.
Our
review
summarized
recent
clinical
improvements
blocking
tactics,
including
combinatorial
treatment
immunogenic
death
(ICD)
inducers
which
may
aid
future
researchers
creating
more
cancer-fighting
strategies.
Journal of Hematology & Oncology,
Journal Year:
2022,
Volume and Issue:
15(1)
Published: March 18, 2022
Abstract
Research
on
tumor
immunotherapy
has
made
tremendous
progress
in
the
past
decades,
with
numerous
studies
entering
clinical
evaluation.
The
cancer
vaccine
is
considered
a
promising
therapeutic
strategy
of
solid
tumors.
Cancer
stimulates
anti-tumor
immunity
antigens,
which
could
be
delivered
form
whole
cells,
peptides,
nucleic
acids,
etc
.
Ideal
vaccines
overcome
immune
suppression
tumors
and
induce
both
humoral
cellular
immunity.
In
this
review,
we
introduced
working
mechanism
summarized
four
platforms
for
development.
We
also
highlighted
research
vaccines,
especially
focusing
their
application
efficacy,
might
hopefully
facilitate
future
design
vaccine.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2022,
Volume and Issue:
41(1)
Published: April 15, 2022
Abstract
Glioblastoma
(GBM)
is
the
most
common
high-grade
primary
malignant
brain
tumor
with
an
extremely
poor
prognosis.
Given
survival
currently
approved
treatments
for
GBM,
new
therapeutic
strategies
are
urgently
needed.
Advances
in
decades
of
investment
basic
science
glioblastoma
rapidly
translated
into
innovative
clinical
trials,
utilizing
improved
genetic
and
epigenetic
profiling
as
well
microenvironment
immune
system
interactions.
Following
these
encouraging
findings,
immunotherapy
including
checkpoint
blockade,
chimeric
antigen
receptor
T
(CAR
T)
cell
therapy,
oncolytic
virotherapy,
vaccine
therapy
have
offered
hope
improving
GBM
outcomes;
ongoing
studies
using
combinatorial
therapies
aim
minimizing
adverse
side-effects
augmenting
antitumor
responses.
In
addition,
techniques
to
overcome
blood-brain
barrier
(BBB)
targeted
delivery
being
tested
trials
patients
recurrent
GBM.
Here,
we
set
forth
rationales
promising
treating
review
potential
novel
agents,
current
status
preclinical
discuss
challenges
future
perspectives
immuno-oncology.
Journal of Hematology & Oncology,
Journal Year:
2022,
Volume and Issue:
15(1)
Published: July 16, 2022
Chemotherapy
combined
with
or
without
targeted
therapy
is
the
fundamental
treatment
for
metastatic
colorectal
cancer
(mCRC).
Due
to
adverse
effects
of
chemotherapeutic
drugs
and
biological
characteristics
tumor
cells,
it
difficult
make
breakthroughs
in
traditional
strategies.
The
immune
checkpoint
blockades
(ICB)
has
made
significant
progress
advanced
malignant
tumors,
patients
who
benefit
from
this
may
obtain
a
long-lasting
response.
Unfortunately,
immunotherapy
only
effective
limited
number
microsatellite
instability-high
(MSI-H),
segment
initial
responders
can
subsequently
develop
acquired
resistance.
From
September
4,
2014,
first
anti-PD-1/PD-L1
drug
Pembrolizumab
was
approved
by
FDA
second-line
melanoma.
Subsequently,
mCRC
2017.
Immunotherapy
rapidly
developed
past
7
years.
in-depth
research
ICB
indicated
that
mechanism
immune-resistance
become
gradually
clear,
new
predictive
biomarkers
are
constantly
emerging.
Clinical
trials
examining
effect
checkpoints
actively
carried
out,
order
produce
patients.
This
review
summarizes
strategies
patients,
discusses
application
treatment,
outlines
potential
markers
efficacy,
lists
key
results
clinical
trials,
collects
recent
basic
results,
provide
theoretical
basis
practical
direction
Chemical Reviews,
Journal Year:
2024,
Volume and Issue:
124(9), P. 5505 - 5616
Published: April 16, 2024
The
recent
emergence
of
nanomedicine
has
revolutionized
the
therapeutic
landscape
and
necessitated
creation
more
sophisticated
drug
delivery
systems.
Polymeric
nanoparticles
sit
at
forefront
numerous
promising
designs,
due
to
their
unmatched
control
over
physiochemical
properties
such
as
size,
shape,
architecture,
charge,
surface
functionality.
Furthermore,
polymeric
have
ability
navigate
various
biological
barriers
precisely
target
specific
sites
within
body,
encapsulate
a
diverse
range
cargo
efficiently
release
this
in
response
internal
external
stimuli.
However,
despite
these
remarkable
advantages,
presence
wider
clinical
application
is
minimal.
This
review
will
provide
comprehensive
understanding
vehicles.
affecting
be
outlined
first,
followed
by
description
nanoparticle
designs
preparation
methods,
beginning
with
polymers
on
which
they
are
based.
meticulously
explore
current
performance
against
myriad
diseases
including
cancer,
viral
bacterial
infections,
before
finally
evaluating
advantages
crucial
challenges
that
determine
potential
decades
come.
Acta Pharmaceutica Sinica B,
Journal Year:
2022,
Volume and Issue:
12(7), P. 3028 - 3048
Published: March 1, 2022
Compared
with
traditional
drug
therapy,
nanomedicines
exhibit
intriguing
biological
features
to
increase
therapeutic
efficiency,
reduce
toxicity
and
achieve
targeting
delivery.
This
review
provides
a
snapshot
of
that
have
been
currently
launched
or
in
the
clinical
trials,
which
manifests
diversified
trend
carrier
types,
applied
indications
mechanisms
action.
From
perspective
indications,
this
article
presents
an
overview
applications
involving
prevention,
diagnosis
treatment
various
diseases,
include
cancer,
infections,
blood
disorders,
cardiovascular
immuno-associated
diseases
nervous
system
etc.
Moreover,
some
considerations
perspectives
research
development
facilitate
their
translations
clinic.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Dec. 13, 2023
With
the
development
and
regulatory
approval
of
immune
checkpoint
inhibitors
adoptive
cell
therapies,
cancer
immunotherapy
has
undergone
a
profound
transformation
over
past
decades.
Recently,
therapeutic
vaccines
have
shown
promise
by
eliciting
de
novo
T
responses
targeting
tumor
antigens,
including
tumor-associated
antigens
tumor-specific
antigens.
The
objective
was
to
amplify
diversify
intrinsic
repertoire
cells.
However,
complete
realization
these
capabilities
remains
an
ongoing
pursuit.
Therefore,
we
provide
overview
current
landscape
in
this
review.
range
antigen
selection,
delivery
systems
strategic
nuances
underlying
effective
presentation
pioneered
vaccine
design.
Furthermore,
review
addresses
status
clinical
trials
discusses
their
strategies,
focusing
on
immunogenicity
anti-tumor
efficacy
assessment.
attempts
toward
developing
not
yielded
breakthrough
outcomes
due
significant
challenges,
microenvironment
suppression,
optimal
candidate
identification,
response
evaluation,
manufacturing
acceleration.
field
is
poised
overcome
hurdles
improve
patient
future
acknowledging
complexities
persistently
striving
surmount
inherent
constraints.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: Oct. 11, 2022
Immune
checkpoint
therapy
via
PD-1
antibodies
has
shown
exciting
clinical
value
and
robust
therapeutic
potential
in
practice.
It
can
significantly
improve
progression-free
survival
overall
survival.
Following
surgery,
radiotherapy,
chemotherapy,
targeted
therapy,
cancer
treatment
now
entered
the
age
of
immunotherapy.
Although
immunotherapy
remarkable
efficacy,
it
also
suffers
from
limitations
such
as
irAEs,
cytokine
storm,
low
response
rate,
etc.
In
this
review,
we
discuss
basic
classification,
research
progress,
Besides,
by
combining
resistance
mechanism
with
analysis
combination
give
our
insights
into
development
new
anticancer
strategies.
